
Helix BioPharma discovers, develops, and seeks licensing for pharmaceuticals to prevent and treat cancer. The company's drug candidates include treatments for female conditions such as human papillomavirus (HPV), a precursor to cervical cancer; common forms of lung cancer such as andenocarcinoma; and potential therapies for breast and prostate cancers. To help fund its drug discovery operations, Helix BioPharma distributes pharmaceuticals and other products for conditions such as gastrointestinal, orthopedic, and immune system disorders in Canada through subsidiary Rivex Pharma.

The German drug company -- seller of popular over-the-counter remedies Zantac and Dulcolax, as well as prescription Flomax for enlarged prostate -- makes a host of prescription and OTC products, not to mention fine chemicals and pet medications. Its prescription drugs include treatments for respiratory ailments, hypertension, HIV, and depression. Boehringer also offers cold, gastrointestinal, and pain remedies, as well as vaccines, drugs, and nutritionals for farm animals and pets. The company operates worldwide. The founding Boehringer family controls the company through parent company C.H. Boehringer Sohn.

China Sky One Medical, Inc. is engaged in the development, manufacture, marketing and sale of over-the-counter, branded nutritional supplements and over-the-counter plant and herb based pharmaceutical and medicinal products. Its principal products are external use Traditional Chinese Herbal Remedies/Medicines (TCM). The Company is also an integrated manufacturer, marketer and distributor of external use Chinese medicine products sold primarily in China and through Chinese domestic pharmaceutical chains. The Company sells both its own manufactured products, as well as medicinal and pharmaceutical products manufactured by others in China. All of its business is conducted through its wholly owned subsidiary, American California Pharmaceutical Group, Inc. (ACPG) which, in turn, wholly owns Harbin Tian Di Ren Medical Science and Technology Company (TDR). On April 3, 2008, TDR completed its acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.

MaxCyte will put your blood cells to work. Its cell loading technology uses blood cells instead of viral vectors to transport gene therapies to target sites, increasing their safety and efficacy. The company partners with drug makers to help them develop more effective therapies in a shorter amount of time. Partners include AlphaVax, Sangamo BioSciences, and United Therapeutics. MaxCyte is also working on its own therapies, including potential treatments for chronic lymphocytic leukemia, lymphoma, and breast and ovarian cancer. CEO Douglas Doerfler and other backers control the company after EntreMed spun it off.

MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. MAPP company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals.

Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

CeMines Biologics, LLC company is working on more accurate, simple blood tests to diagnose lung, breast, prostate, and other cancers. The firm's CeMines Molecular FingerPrinting technology uses biostatistics to determine if disease biomarkers found in a patient's blood sample indicate the likelihood of cancer. Its lead product candidate, CeMines CellCorrect LAb, detects patterns of key antibodies that indicate cancer cells are present. Noted researcher Toomas Neuman, whose use of stem cells to treat Parkinson's disease triggered a national debate, founded the company in 2000 with several other officers of the company, which is led by CEO Richard Cavalli.
Helicon Therapeutics is a development-stage biotechnology firm working on new therapies for memory loss and other cognition disorders. The company's research and development efforts focus on a protein that controls the signal pathway key to forming long-term memories. Scientists working for Helicon Therapeutics discovered the protein while studying the fruit fly genome. The company is working on drugs to not only maintain memory but also possibly to prevent memories from forming in the first place. Lead drug candidate HT-0712 has shown the ability to improve long-term memory in rats. Other candidates are in early stages of development.

EXACT Sciences Corporation company was founded in 1995 and is based in Madison, Wisconsin. Exact Sciences Corporation, a molecular diagnostics company, focuses on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Its non-invasive stool-based DNA (sDNA) screening technology includes proprietary and patented methods that isolate and analyze human DNA present in stool to screen for the presence of colorectal pre-cancer and cancer. The company's principal product includes ColoSure, a non-invasive laboratory developed stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. Exact Sciences Corporation has strategic alliances with Laboratory Corporation of America Holdings, the MAYO Foundation for Medical Education and Research, and Genzyme Corporation.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)






